RT Journal Article
SR Electronic
T1 Is the infection of the SARS-CoV-2 Delta variant associated with the outcomes of COVID-19 patients?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.05.21262783
DO 10.1101/2021.10.05.21262783
A1 Gunadi,
A1 Hakim, Mohamad Saifudin
A1 Wibawa, Hendra
A1 Marcellus,
A1 Setiawaty, Vivi
A1 Slamet,
A1 Trisnawati, Ika
A1 Supriyati, Endah
A1 Khair, Riat El
A1 Iskandar, Kristy
A1 Afiahayati,
A1 Siswanto,
A1 Irene,
A1 Anggorowati, Nungki
A1 Daniwijaya, Edwin Widyanto
A1 Agung Nugrahaningsih, Dwi Aris
A1 Puspadewi, Yunika
A1 Puspitarani, Dyah Ayu
A1 Tania, Irene
A1 Vujira, Khanza Adzkia
A1 Ardlyamustaqim, Muhammad Buston
A1 Gabriela, Gita Christy
A1 Eryvinka, Laudria Stella
A1 Nirmala, Bunga Citta
A1 Geometri, Esensi Tarian
A1 Darutama, Abirafdi Amajida
A1 Kuswandani, Anisa Adityarini
A1 Lestari,
A1 Irianingsih, Sri Handayani
A1 Khoiriyah, Siti
A1 Lestari, Ina
A1 Ananda, Nur Rahmi
A1 Arguni, Eggi
A1 Nuryastuti, Titik
A1 Wibawa, Tri
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/10/07/2021.10.05.21262783.abstract
AB Background SARS-CoV-2 Delta variant (B.1.617.2) has been responsible for the current increase in COVID-19 infectivity rate worldwide. We compared the impact of the Delta variant and non-Delta variant on the COVID-19 outcomes in patients from Yogyakarta and Central Java provinces, Indonesia.Methods We ascertained 161 patients, 69 with the Delta variant and 92 with the non-Delta variant. The Illumina MiSeq next-generation sequencer was used to perform the whole genome sequences of SARS-CoV-2.Results The mean age of patients with Delta and the non-Delta variant was 27.3 ± 20.0 and 43.0 ± 20.9 (p=3×10−6). The patients with Delta variant consisted of 23 males and 46 females, while the patients with the non-Delta variant involved 56 males and 36 females (p=0.001). The Ct value of the Delta variant (18.4 ± 2.9) was significantly lower than the non-Delta variant (19.5 ± 3.8) (p=0.043). There was no significant difference in the hospitalization and mortality of patients with Delta and non-Delta variants (p=0.80 and 0.29, respectively). None of the prognostic factors was associated with the hospitalization, except diabetes with an OR of 3.6 (95% CI=1.02-12.5; p=0.036). Moreover, the patients with the following factors have been associated with higher mortality rate than patients without the factors: age ≥65 years, obesity, diabetes, hypertension, and cardiovascular disease with the OR of 11 (95% CI=3.4-36; p=8×10−5), 27 (95% CI=6.1-118; p=1×10−5), 15.6 (95% CI=5.3-46; p=6×10−7), 12 (95% CI=4-35.3; p=1.2×10−5), and 6.8 (95% CI=2.1-22.1; p=0.003), respectively. Multivariate analysis showed that age ≥65 years, obesity, diabetes, and hypertension were the strong prognostic factors for the mortality of COVID-19 patients with the OR of 3.6 (95% CI=0.58-21.9; p=0.028), 16.6 (95% CI=2.5-107.1; p=0.003), 5.5 (95% CI=1.3-23.7; p=0.021), and 5.8 (95% CI=1.02-32.8; p=0.047), respectively.Conclusions We show that the patients infected by the SARS-CoV-2 Delta variant have a lower Ct value than the patients infected by the non-Delta variant, implying that the Delta variant has a higher viral load, which might cause a more transmissible virus among humans. However, the Delta variant does not affect the COVID-19 outcomes in our patients. Our study also confirms the older age and comorbidity increase the mortality rate of COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Ministry of Education, Culture, Research and Technology, Indonesia, funded our study. The funders had no role in study design, data collection, and analysis, decision to publish, or manuscript preparation. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital approved our study (KE/FK/0563/EC/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in the submission. The sequence and metadata are shared through GISAID (www.gisaid.org).CIconfidence intervalORodds ratioVOCvariant of concern